We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

134 hedge funds and large institutions have $847M invested in Verve Therapeutics in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 24

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

40% more call options, than puts

Call options by funds: $7M | Put options by funds: $4.99M

11% more funds holding

Funds holding: 121 → 134 (+13)

0.31% more ownership

Funds ownership: 99.94% → 100.25% (+0.31%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

27% less capital invested

Capital invested by funds: $1.16B → $847M (-$313M)

Holders
134
Holders Change
+13
Holders Change %
+10.74%
% of All Funds
2.13%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
27
Increased
58
Reduced
24
Closed
14
Calls
$7M
Puts
$4.99M
Net Calls
+$2M
Net Calls Change
+$1.64M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$11.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.7M
3
CC
Casdin Capital
New York
+$9.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.55M
5
LGM
Logos Global Management
California
+$3.46M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$9.55M
2
NHAS
Novo Holdings A/S
Denmark
-$9.38M
3
Citadel Advisors
Citadel Advisors
Florida
-$7.39M
4
RG
Redmile Group
California
-$4.06M
5
PHS
PFM Health Sciences
California
-$3.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northwestern Mutual Wealth Management
126
Northwestern Mutual Wealth Management
Wisconsin
$93 +$113 +7 New
CPG
127
Cornerstone Planning Group
New Jersey
$27 +$32 +2 New
FFA
128
Farther Finance Advisors
California
$27 +$32 +2 New
AF
129
Allworth Financial
California
$14 -$1.56K -97 -99%
IA
130
IFP Advisors
Florida
$13 -$81 -5 -83%
FGAM
131
Financial Gravity Asset Management
Texas
$6 -$290 -18 -95%
NHAS
132
Novo Holdings A/S
Denmark
– -$9.38M -500,000 Closed
PHS
133
PFM Health Sciences
California
– -$3.49M -186,087 Closed
JFG
134
Jefferies Financial Group
New York
– -$3.33M -177,716 Closed
Marshall Wace
135
Marshall Wace
United Kingdom
– -$961K -51,235 Closed
Verition Fund Management
136
Verition Fund Management
Connecticut
– -$509K -27,153 Closed
Hudson Bay Capital Management
137
Hudson Bay Capital Management
Connecticut
– -$422K -22,500 Closed
HF
138
HRT Financial
New York
– -$237K -12,669 Closed
DTL
139
Dynamic Technology Lab
Singapore
– -$207K -11,051 Closed
Qube Research & Technologies (QRT)
140
Qube Research & Technologies (QRT)
United Kingdom
– -$192K -10,224 Closed
CM
141
Caption Management
Oklahoma
– -$91.8K -5,700 Closed
Point72 Asset Management
142
Point72 Asset Management
Connecticut
– -$60.9K -3,250 Closed
Simplex Trading
143
Simplex Trading
Illinois
– -$5.22K -324 Closed
Russell Investments Group
144
Russell Investments Group
United Kingdom
– -$431 -23 Closed
C
145
Covestor
United Kingdom
– -$16 -1 -13%
M
146
MOTCO
Texas
– -$19 -1 Closed
CAL
147
Capital Advisors Ltd
Ohio
– +$499 +31 New
2 3 4 5
6

VERV Hedge Fund Activity: Q3 2023 in Review

134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2023, worth a combined $847M — down 27% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VERV positions and 14 closed out — a net gain of 13 holders — while 58 added to existing stakes and 24 trimmed.

The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Avidity Partners Management, cutting an estimated $9.55M.

  • 134 institutional investors held Verve Therapeutics (VERV) as of Q3 2023, up from 121 in Q2 2023.
  • Funds reported $847M of Verve Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
  • 27 funds opened new Verve Therapeutics positions in Q3 2023 and 14 closed out, a net change of +13 holders.
  • The largest Verve Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $11.9M added.
  • The largest Verve Therapeutics seller in Q3 2023 was Avidity Partners Management, an estimated $9.55M sold.

Based on aggregated 13F filings for Q3 2023.